With growing interest in sustainable and bio-based cannabinoids, and after completing a strategic review of Hyasynth including their intellectual property (IP) and R&D platforms, Organigram remains excited about Hyasynth’s future and growth plans M
Not for Distribution to United States Newswire Services or for Dissemination in the United States HALIFAX, Nova Scotia--(BUSINESS WIRE)--Appili Therapeutics Inc. (TSX:APLI) (the “Company” or “Appili”), a biopharmaceutical company focused on drug
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™” is pleased to provide a year-end summary of its major milesto
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. (NASDAQ: IMV; TSX: IMV), (“IMV” or “the Company”), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid tu
BURLINGTON, Ontario--(BUSINESS WIRE)--$DOSE--Today, Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) and McMaster University (“McMaster”) are pleased to announce that the ongoing development of an orally delivered vaccine can
Scandinavian Biopharma has obtained a global license for VaxAlta Inc.’s intellectual property for the development of a new Campylobacter jejuni vaccine for humans. C. jejuni is one of the most common causes of bacterial diarrheal illness in humans.
Agriculture e-commerce leader partners with trusted retailer to extend fulfillment to Northeast WINNIPEG, Manitoba--(BUSINESS WIRE)--Farmers Edge Inc. (“Farmers Edge” or the “Company”) (TSX: FDGE), a pure-play digital agriculture company, today
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™” is pleased to announce that Doug Drysdale, Cybin’s Chief Ex
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to discover and develop
Recognition of leadership position within both the food & beverage and cannabis product categories a validation of the Company’s comprehensive sector strategy VANCOUVER, British Columbia--(BUSINESS WIRE)--BevCanna Enterprises Inc. (CSE:BEV, Q:BVNNF
Sign up for one of BAM's newsletter to learn more about bioscience, happenings in Manitoba's bioeconomy, industry conferences, and BAM training events.